🔗 Permalink

Inventor profile of:

Kennett Sprogøe

City:

Holte

Country:

Denmark

Published Applications:

Last publication date:

2025-10-02

Top Assignees for applications by Kennett Sprogøe

The entities that hold a legal rights for patent applications filed by inventor Sprogøe Kennett:

Ascendis Pharma Bone Diseases A/S 13 Hellerup, Denmark
ASCENDIS PHARMA GROWTH DISORDERS A/S 12 Hellerup, Denmark
Ascendis Pharma A/S 3 Hellerup, Denmark
Ascendis Pharma Endocrinology Division A/S 3 Hellerup, Denmark
Ascendis Pharma A/S 1 Hellerup, Germany
Ascendis Pharma Ophthamology Division A/S 1 Hellerup, Denmark

Recent patent applications by Sprogøe Kennett

Kennett Sprogøe from Holte, DK has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-10-02

US20250302924A1

Human necessities

Controlled-Release PTH Compound

#2 | 2025-08-28

US20250268988A1

Human necessities

PTH Prodrugs

#3 | 2025-04-17

US20250121074A1

Human necessities

CNP PRODRUGS WITH CARRIER ATTACHMENT AT THE RING MOIETY

#4 | 2025-03-20

US20250090671A1

Human necessities

CNP PRODRUGS

#5 | 2024-11-07

US20240366730A1

Human necessities

Long-Acting Growth Hormone Treatment

#6 | 2024-09-26

US20240316153A1

Human necessities

CNP PRODRUGS WITH LARGE CARRIER MOIETIES

#7 | 2024-07-25

US20240245755A1

Human necessities

Controlled-release PTH compound

#8 | 2024-05-30

US20240173385A1

Human necessities

PTH Compounds with Low Peak-To-Trough Ratios

#9 | 2024-04-18

US20240123038A1

Human necessities

PTH prodrugs

#10 | 2023-11-30

US20230381284A1

Human necessities

Controlled-release PTH compound

#11 | 2023-10-12

US20230321198A1

Human necessities

Dosage Regimen for a Controlled-Release PTH Compound

#12 | 2023-09-28

US20230302091A1

Human necessities

Combination Therapy with Controlled-Release CNP Agonists

#13 | 2023-08-10

US20230248836A1

Human necessities

Controlled-release PTH compound

#14 | 2023-07-13

US20230218722A1

Human necessities

PTH compounds with low peak-to-trough ratios

#15 | 2023-04-20

US20230121525A1

Human necessities

PTH prodrugs

#16 | 2023-04-13

US20230116809A1

Human necessities

PREVENTION AND TREATMENT OF OCULAR CONDITIONS

#17 | 2023-04-13

US20230116746A1

Human necessities

CNP PRODRUGS

#18 | 2023-04-06

US20230103820A1

Human necessities

Controlled-release CNP agonists with low initial NPR-B activity

#19 | 2022-12-29

US20220409700A1

Human necessities

CONTROLLED-RELEASE CNP AGONISTS WITH REDUCED SIDE-EFFECTS

#20 | 2022-10-20

US20220331438A1

Human necessities

CNP prodrugs with carrier attachment at the ring moiety

#21 | 2022-07-07

US20220211817A1

Human necessities

CONTROLLED-RELEASE CNP AGONISTS WITH LOW NPR-C BINDING

#22 | 2022-03-24

US20220088206A1

Human necessities

Controlled-release CNP agonists with increased NEP stability

#23 | 2022-01-13

US20220008516A1

Human necessities

PTH Prodrugs

#24 | 2021-07-22

US20210220442A1

Human necessities

PEGylated recombinant human growth hormone compounds

#25 | 2021-03-11

US20210069339A1

Human necessities

CNP PRODRUGS

#26 | 2020-12-03

US20200376089A1

Human necessities

PTH PRODRUGS

#27 | 2020-11-19

US20200360488A1

Human necessities

PTH COMPOUNDS WITH LOW PEAK-TO-TROUGH RATIOS

#28 | 2020-11-19

US20200360487A1

Human necessities

PTH PRODRUGS

#29 | 2020-09-03

US20200276270A1

Human necessities

Combination therapy with controlled-release CNP agonists

#30 | 2020-01-23

US20200023041A1

Human necessities

Dosage regimen for a controlled-release PTH compound

#31 | 2019-10-31

US20190328841A1

Human necessities

Controlled-release CNP agonists with reduced side-effects

#32 | 2019-10-31

US20190328840A1

Human necessities

Controlled-release CNP agonists with low initial NPR-B activity

#33 | 2019-09-19

US20190282668A1

Human necessities

PTH compounds with low peak-to-trough ratios

#34 | 2019-08-22

US20190255183A1

Human necessities

CNP PRODRUGS

#35 | 2019-07-25

US20190224329A1

Human necessities

Incremental Dose Finding in Controlled-Release PTH Compounds

#36 | 2019-06-27

US20190192634A1

Human necessities

PEGylated recombinant human growth hormone compounds

#37 | 2019-04-11

US20190105400A1

Human necessities

Carrier-linked treprostinil prodrugs

#38 | 2019-01-24

US20190022237A1

Human necessities

Controlled-release CNP agonists with increased NEP stability

#39 | 2019-01-03

US20190000926A1

Human necessities

Controlled-release CNP agonists with low NPR-C binding

#40 | 2017-11-02

US20170312342A1

Human necessities

Long-acting growth hormone treatment

#41 | 2017-04-27

US20170112939A1

Human necessities

PREVENTION AND TREATMENT OF OCULAR CONDITIONS

#42 | 2014-10-09

US20140303245A1

Human necessities

Sustained release composition of prostacyclin

#43 | 2014-10-02

US20140296150A1

Human necessities

Carrier-linked treprostinil prodrugs

InventorID:

1856795 ⎘